Abstract:
Despite adequate hypolipidemic therapy, the risk of cardiovascular complications remains
high. This review provides a scientific overview of current LDL receptor data, the importance of PCSK9 in receptor-level regulation, and the influence of lipoprotein (a) and the role of lipoprotein-associated phospholipase A2 in the development and progression of atherosclerosis.
LDL receptors play a crucial role in the exchange of cholesterol LDL in the body. It has been shown that PCSK9 is involved in the destruction of LDL receptors, being the primary regulator of its expression on the cell surface. There is strong evidence of association between a continuous and independent high-level Lp (a) and increased risk of CVD development and progression of atherosclerosis in various vascular structures.
